瑞舒伐他汀对杂合子家族性高胆固醇血症儿童颈动脉内中膜厚度的影响:CHARON研究
CHARON研究评估了瑞舒伐他汀治疗2年对杂合子家族性高胆固醇血症(HeFH)儿童颈动脉内中膜厚度(IMT)的影响。197例HeFH患儿接受瑞舒伐他汀治疗,并与65例年龄匹配的未患病同胞比较。结果显示治疗2年后HeFH患儿颈动脉IMT进展显著低于未治疗同胞,两组间IMT差异不再显著。
要点
- HeFH患儿基线颈动脉IMT显著高于未患病同胞。
- 瑞舒伐他汀治疗2年使HeFH患儿IMT年进展量显著低于同胞。
- 治疗2年后两组间平均颈动脉IMT差异无统计学意义。
核心结论
- 在≥6岁HeFH患儿中,瑞舒伐他汀治疗2年可显著减缓颈动脉IMT进展,支持早期启动他汀降低LDL-C。
研究设计与样本
- 开放标签研究,纳入197例6-<18岁HeFH患儿和65例年龄匹配未患病同胞,瑞舒伐他汀起始5 mg每日一次,按年龄上调至10 mg或20 mg,治疗2年。
- 基线及12、24个月超声测量双侧颈动脉三个部位(颈总动脉、颈动脉球部、颈内动脉)的IMT,采用线性混合效应模型比较。
主要发现
- 基线平均颈动脉IMT在HeFH患儿为0.397±0.049 mm,显著高于未患病同胞的0.377±0.045 mm(P=0.001)。
- 2年随访期间,颈动脉IMT年变化量在HeFH患儿为0.0054 mm/y(95%CI 0.0030-0.0082),在未患病同胞为0.0143 mm/y(95%CI 0.0095-0.0192),组间差异P=0.002。
- 治疗2年末,HeFH患儿与未患病同胞的平均颈动脉IMT分别为0.408±0.043 mm和0.402±0.042 mm,差异无统计学意义(P=0.2)。
临床怎么用
- 对于≥6岁HeFH患儿,可考虑早期启动瑞舒伐他汀治疗以降低LDL-C并减缓颈动脉IMT进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant disorder leading to premature atherosclerosis. Children with HeFH exhibit early signs of atherosclerosis manifested by increased carotid intima-media thickness (IMT). In this study, we assessed the effect of 2-year treatment with rosuvastatin on carotid IMT in children with HeFH. METHODS: Children with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1 mmol/L in combination with other risk factors received rosuvastatin for 2 years, starting at 5 mg once daily, with uptitration to 10 mg (age, 6-<10 years) or 20 mg (age, 10-<18 years). Carotid IMT was assessed by ultrasonography at baseline and 12 and 24 months in all patients and in age-matched unaffected siblings. Carotid IMT was measured at 3 locations (common carotid artery, carotid bulb, internal carotid artery) in both the left and right carotid arteries. A linear mixed-effects model was used to evaluate differences in carotid IMT between children with HeFH and the unaffected siblings. P values were adjusted for age, sex, carotid artery site, and family relations. RESULTS: At baseline, mean±SD carotid IMT was significantly greater for the 197 children with HeFH compared with the 65 unaffected siblings (0.397±0.049 and 0.377±0.045 mm, respectively; P=0.001). During 2 years of follow-up, the change in carotid IMT was 0.0054 mm/y (95% confidence interval, 0.0030-0.0082) in children with HeFH and 0.0143 mm/y (95% confidence interval, 0.0095-0.0192) in unaffected siblings (P=0.002). The end-of-study difference in mean carotid IMT between children with HeFH and unaffected siblings after 2 years was no longer significant (0.408±0.043 and 0.402±0.042 mm, respectively; P=0.2). CONCLUSIONS: In children with HeFH who were ≥6 years of age, carotid IMT was significantly greater at baseline compared with unaffected siblings. Rosuvastatin treatment for 2 years resulted in significantly less progression of increased carotid IMT in children with HeFH than untreated unaffected siblings. As a result, no difference in carotid IMT could be detected between the 2 groups after 2 years of rosuvastatin. These findings support the value of early initiation of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01078675.
引用
- Braamskamp MJAM, Langslet G, McCrindle BW, et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017. PMID: 28592434. doi:10.1161/CIRCULATIONAHA.116.025158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。